BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses the company’s cell therapy for corneal endothelial disease.
Kunst said the company is nearing completion of its phase 1/2 trial, and recent data have provided valuable insight as Aurion moves into phase 3 trials and its commercialization strategy.
“We have a product that has been in over 130 subjects in our early trials,” he said. “We have a product that we can scale massively and really take this around the world to end the (Read more...)